BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Luo X, Huang Y, Chen Y, Tu Z, Hu J, Tavis JE, Huang A, Hu Y. Association of Hepatitis B Virus Covalently Closed Circular DNA and Human APOBEC3B in Hepatitis B Virus-Related Hepatocellular Carcinoma. PLoS One 2016;11:e0157708. [PMID: 27310677 DOI: 10.1371/journal.pone.0157708] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Prifti GM, Moianos D, Giannakopoulou E, Pardali V, Tavis JE, Zoidis G. Recent Advances in Hepatitis B Treatment. Pharmaceuticals (Basel) 2021;14:417. [PMID: 34062711 DOI: 10.3390/ph14050417] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Ortega-Prieto AM, Dorner M. Immune Evasion Strategies during Chronic Hepatitis B and C Virus Infection. Vaccines (Basel). 2017;5:pii: E24. [PMID: 28862649 DOI: 10.3390/vaccines5030024] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
3 Chen Y, Hu J, Cai X, Huang Y, Zhou X, Tu Z, Hu J, Tavis JE, Tang N, Huang A, Hu Y. APOBEC3B edits HBV DNA and inhibits HBV replication during reverse transcription. Antiviral Res 2018;149:16-25. [PMID: 29129707 DOI: 10.1016/j.antiviral.2017.11.006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
4 Tantiwetrueangdet A, Panvichian R, Sornmayura P, Sueangoen N, Leelaudomlipi S. Reduced HBV cccDNA and HBsAg in HBV-associated hepatocellular carcinoma tissues. Med Oncol 2018;35:127. [PMID: 30116916 DOI: 10.1007/s12032-018-1191-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
5 Ji M, Hu K. Recent advances in the study of hepatitis B virus covalently closed circular DNA. Virol Sin. 2017;32:454-464. [PMID: 29280054 DOI: 10.1007/s12250-017-4009-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.4] [Reference Citation Analysis]
6 Van Damme E, Vanhove J, Severyn B, Verschueren L, Pauwels F. The Hepatitis B Virus Interactome: A Comprehensive Overview. Front Microbiol 2021;12:724877. [PMID: 34603251 DOI: 10.3389/fmicb.2021.724877] [Reference Citation Analysis]
7 Wang T, Jin W, Huang Q, Li H, Zhu Y, Liu H, Cai H, Wang J, Wang R, Xiao X, Zhao Y, Zou W. Clinical Efficacy and Safety of Eight Traditional Chinese Medicine Combined with Entecavir in the Treatment of Chronic Hepatitis B Liver Fibrosis in Adults: A Network Meta-Analysis. Evid Based Complement Alternat Med 2020;2020:7603410. [PMID: 33062022 DOI: 10.1155/2020/7603410] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
8 Wang Z, Chen Y, Deng H, Zhen X, Xiong J, Hu Y. Quantification of intrahepatic cccDNA in HBV associated hepatocellular carcinoma by improved ddPCR method. J Virol Methods 2022;299:114334. [PMID: 34688781 DOI: 10.1016/j.jviromet.2021.114334] [Reference Citation Analysis]
9 Vural S, Simon R, Krushkal J. Correlation of gene expression and associated mutation profiles of APOBEC3A, APOBEC3B, REV1, UNG, and FHIT with chemosensitivity of cancer cell lines to drug treatment. Hum Genomics 2018;12:20. [PMID: 29642934 DOI: 10.1186/s40246-018-0150-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
10 Yan QH, Xu DG, Shen YF, Yuan DL, Bao JH, Li HB, Lv YG. Observation of the effect of targeted therapy of 64-slice spiral CT combined with cryoablation for liver cancer. World J Gastroenterol 2017; 23(22): 4080-4089 [PMID: 28652661 DOI: 10.3748/wjg.v23.i22.4080] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
11 Hu J, Qiao M, Chen Y, Tang H, Zhang W, Tang D, Pi S, Dai J, Tang N, Huang A, Hu Y. Cyclin E2-CDK2 mediates SAMHD1 phosphorylation to abrogate its restriction of HBV replication in hepatoma cells. FEBS Lett 2018;592:1893-904. [PMID: 29782647 DOI: 10.1002/1873-3468.13105] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
12 Mak LY, Huang Q, Wong DK, Stamm L, Cheung KS, Ko KL, Yan R, Ouyang L, Fung J, Seto WK, Yuen MF. Residual HBV DNA and pgRNA viraemia is associated with hepatocellular carcinoma in chronic hepatitis B patients on antiviral therapy. J Gastroenterol 2021;56:479-88. [PMID: 33772643 DOI: 10.1007/s00535-021-01780-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Pan W, Li W, Zhao J, Huang Z, Chen S, Wang C, Xue Y, Huang F, Fang Q, Wang J, Brand D, Zheng SG. lncRNA-PDPK2P promotes hepatocellular carcinoma progression through the PDK1/AKT/Caspase 3 pathway. Mol Oncol. 2019;13:2246-2258. [PMID: 31368655 DOI: 10.1002/1878-0261.12553] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
14 Wang T, Zhou X, Liu H, Wang J, Zhang P, Zhu Y, Li K, Wei S, Li H, Wang L, Wang R, Zhao Y. Fuzheng Huayu capsule as an adjuvant treatment for HBV-related cirrhosis: A systematic review and meta-analysis. Phytother Res 2018;32:757-68. [PMID: 29235181 DOI: 10.1002/ptr.6009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
15 Prescott NA, Bram Y, Schwartz RE, David Y. Targeting Hepatitis B Virus Covalently Closed Circular DNA and Hepatitis B Virus X Protein: Recent Advances and New Approaches. ACS Infect Dis. 2019;5:1657-1667. [PMID: 31525994 DOI: 10.1021/acsinfecdis.9b00249] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
16 Zou J, Wang C, Ma X, Wang E, Peng G. APOBEC3B, a molecular driver of mutagenesis in human cancers. Cell Biosci 2017;7:29. [PMID: 28572915 DOI: 10.1186/s13578-017-0156-4] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 6.2] [Reference Citation Analysis]
17 Chen Y, Shen B, Zheng X, Long Q, Xia J, Huang Y, Cai X, Wang D, Chen J, Tang N, Huang A, Hu Y. DHX9 interacts with APOBEC3B and attenuates the anti-HBV effect of APOBEC3B. Emerg Microbes Infect 2020;9:366-77. [PMID: 32056513 DOI: 10.1080/22221751.2020.1725398] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
18 Zhang Y, Chen X, Cao Y, Yang Z. Roles of APOBEC3 in hepatitis B virus (HBV) infection and hepatocarcinogenesis. Bioengineered 2021;12:2074-86. [PMID: 34043485 DOI: 10.1080/21655979.2021.1931640] [Reference Citation Analysis]